532440-88-3

Basic information

• Product Name: 2-bromo-5-methoxy-4-methylaniline
• Synonyms: 2-bromo-5-methoxy-4-methylaniline;2-Bromo-5-methoxy-4-methyl-phenylamine
• CAS NO: 532440-88-3
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 216.0751
• Mol File: 532440-88-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 75-77°
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-bromo-5-methoxy-4-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5-methoxy-4-methylaniline(532440-88-3)
• EPA Substance Registry System: 2-bromo-5-methoxy-4-methylaniline(532440-88-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 532440-88-3(Hazardous Substances Data)

Usage

General Description

2-bromo-5-methoxy-4-methylaniline is a chemical compound with the molecular formula C8H10BrNO. It is an aromatic amine with a bromine atom and a methoxy group attached to the benzene ring. The presence of a methoxy group and a methyl group on the benzene ring makes it a substituted aniline derivative. 2-bromo-5-methoxy-4-methylaniline is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and agrochemicals. It can also be used as a building block in organic synthesis. Additionally, it can be used as a reagent in various chemical reactions. Due to its chemical structure and properties, 2-bromo-5-methoxy-4-methylaniline is a valuable compound in the field of organic chemistry and drug development.

Upstream product

• 16452-01-0 ortho-cresidine 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 1072895-84-1 2,4-dichloro-7-methoxy-6-methylquinazoline 

Relevant articles and documents

Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase

G9a-like protein (GLP) and G9a are highly homologous protein lysine methyltransferases (PKMTs) sharing approximately 80% sequence identity in their catalytic domains. GLP and G9a form a heterodimer complex and catalyze mono- and dimethylation of histone H3 lysine 9 and nonhistone substrates. Although they are closely related, GLP and G9a possess distinct physiological and pathophysiological functions. Thus, GLP or G9a selective small-molecule inhibitors are useful tools to dissect their distinct biological functions. We previously reported potent and selective G9a/GLP dual inhibitors including UNC0638 and UNC0642. Here we report the discovery of potent and selective GLP inhibitors including 4 (MS0124) and 18 (MS012), which are >30-fold and 140-fold selective for GLP over G9a and other methyltransferases, respectively. The cocrystal structures of GLP and G9a in the complex with either 4 or 18 displayed virtually identical binding modes and interactions, highlighting the challenges in structure-based design of selective inhibitors for either enzyme.

N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases

The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia: